Should a post‑liver transplant patient with type 2 diabetes and normal renal function who is taking metformin 1000 mg twice daily, empagliflozin (Jardiance) 25 mg daily, and insulin glargine (Lantus) 30 units continue metformin and empagliflozin at discharge?

Continue metformin but hold Jardiance (empagliflozin) at discharge in this early post-liver transplant patient.

Metformin: Continue with Monitoring

Metformin should be continued in this patient with excellent renal function (eGFR >90) 1. The KDIGO 2022 guidelines explicitly state that kidney transplant recipients with T2D and eGFR ≥30 mL/min/1.73 m² should be treated with metformin according to standard CKD recommendations 1. At 6 days post-transplant with stable renal function, metformin 1000 mg twice daily is appropriate and safe.

Key monitoring requirements:

• Check eGFR at least every 3-6 months given transplant status 1
• Hold metformin temporarily if acute illness, dehydration, or procedures with contrast occur 2
• Monitor for vitamin B12 deficiency if used >4 years 1
• Watch for gastrointestinal side effects that could compromise nutrition in early post-transplant period 3

The 2009 transplant management guidelines confirm that oral hypoglycemics can be used post-liver transplant with little concern for interaction with immunosuppressive medications or damage to the transplanted liver 4. Metformin may also provide additional benefits including potential reduction in malignancy risk, which is elevated in transplant recipients 5, 6.

Jardiance (Empagliflozin): Hold at This Time

Empagliflozin should be held at discharge despite the patient's excellent renal function. Here's the algorithmic reasoning:

Reasons to Hold SGLT2 Inhibitors Early Post-Transplant:

1. Infection Risk in Immunosuppressed State: The patient is only 6 days post-transplant and on immunosuppression. SGLT2 inhibitors increase risk of genitourinary infections, particularly mycotic infections 2. In an immunosuppressed patient, this risk is amplified and potentially more serious.

2. Volume Depletion Risk: SGLT2 inhibitors cause osmotic diuresis. Early post-transplant patients require careful volume management to maintain adequate graft perfusion. Volume depletion could compromise the new liver graft 7.

3. Euglycemic DKA Risk: SGLT2 inhibitors carry risk of euglycemic diabetic ketoacidosis, particularly in patients with poor oral intake 2. Post-operative patients often have variable nutritional intake in the early recovery period.

4. Lack of Transplant-Specific Safety Data: While one small study showed empagliflozin was safe in renal transplant recipients >1 year post-transplant 8, there is insufficient data in liver transplant recipients, especially in the immediate post-operative period.

5. Insulin is Preferred Early Post-Transplant: The 2009 transplant guidelines explicitly state that "patients require insulin therapy in the early stages" post-liver transplant 4. The patient is already on Lantus 30 units, which is appropriate for this phase.

When to Consider Reintroducing SGLT2 Inhibitors:

Reassess empagliflozin at 3-6 months post-transplant when:

• Patient is stable on maintenance immunosuppression (not acute phase)
• No active infections
• Stable graft function
• Consistent oral intake
• If additional glycemic control needed beyond metformin and insulin

At that point, empagliflozin may offer significant benefits including improved glycemic control, weight reduction (important as post-transplant weight gain is common), and potential hepatic benefits for preventing graft steatosis 8, 9, 10, 11.

Current Discharge Regimen:

Discharge on:

• Metformin 1000 mg twice daily (continue)
• Lantus 30 units daily (continue, adjust based on glucose monitoring)
• Hold Jardiance 25 mg daily

Follow-up plan:

• Frequent glucose monitoring with insulin dose adjustments
• Check renal function in 2-4 weeks
• Reassess need for empagliflozin at 3-6 months post-transplant once stable on maintenance immunosuppression

Common Pitfalls to Avoid:

• Don't continue all pre-transplant medications reflexively - the early post-transplant period requires different considerations than chronic diabetes management
• Don't underestimate infection risk - immunosuppression makes even minor infections potentially serious
• Don't forget volume status - SGLT2 inhibitors cause diuresis that could compromise graft perfusion early post-transplant
• Don't overlook the adequacy of insulin - insulin remains the safest option for glycemic control in the immediate post-operative period 4